<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754139</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-1388</org_study_id>
    <nct_id>NCT04754139</nct_id>
  </id_info>
  <brief_title>A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population</brief_title>
  <official_title>A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Social Entrepreneurship to Spur Health (SESH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to use a social media mini-application-enabled intervention to successfully&#xD;
      promote the initiation and persistence of pre-exposure prophylaxis (PrEP) among at-risk men&#xD;
      who have sex with men (MSM) and youth in Wuhan and Guangzhou, China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The China National Medical Products Administration (NMPA) recently approved TDF/FTC (Truvada)&#xD;
      for PrEP making it the first HIV prevention medicine available in China. While this is a&#xD;
      significant step in addressing the country's rising rates of new HIV diagnoses,&#xD;
      implementation and scale-up of this resource will be the next challenge.&#xD;
&#xD;
      Three thousand two hundred at-risk youth and young adults will be engaged by word of mouth&#xD;
      and social media. Individuals will be asked to complete a survey of risk and PrEP interest,&#xD;
      to download the study mobile mini-application onto their cell phone, and will be offered an&#xD;
      HIV and syphilis screen. One thousand two hundred of these subjects who are eligible and&#xD;
      willing to start PrEP will be enrolled in the study.&#xD;
&#xD;
      Enrolled participants will undergo baseline laboratory testing before brought to a&#xD;
      collaborating hospital where an established physician will provide TDF/FTC and arrange&#xD;
      follow-up. All subjects will be encouraged to keep using the mini-application for receiving&#xD;
      constant health education and counseling support on HIV/STI prevention, PrEP initiation&#xD;
      and/or adherence management. Subjects on PrEP will be contacted every three months over the&#xD;
      course of two years to answer questions on adherence, adverse effect, and utilization of the&#xD;
      mini-application.&#xD;
&#xD;
      In addition, a PrEP messaging open contest will be organized to assess the best images and&#xD;
      videos to enhance PrEP adherence among those who start PrEP. New content will be developed&#xD;
      using crowdsourcing and introduced into the mini-application at staggered times. The effect&#xD;
      of this content will be evaluated through a stepped wedge approach nested within this single&#xD;
      arm study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PrEP prescriptions</measure>
    <time_frame>2 years</time_frame>
    <description>Number of PrEP prescriptions fulfilled in Wuhan and Guangzhou, China</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Screenings</measure>
    <time_frame>2 years</time_frame>
    <description>Number of HIV screenings performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syphilis screenings</measure>
    <time_frame>2 years</time_frame>
    <description>Number of syphilis screenings performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects retained in PrEP care at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>2 years</time_frame>
    <description>Number of subjects that self-report PrEP adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New HIV infection</measure>
    <time_frame>2 years</time_frame>
    <description>Number of new HIV infections reported in PrEP users</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New syphilis infection</measure>
    <time_frame>2 years</time_frame>
    <description>Number of new syphilis infections reported in PrEP users</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>HIV Preexposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>WeChat mobile mini-application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WeChat mini-application will increase knowledge base about sexual health through interactive health education and counseling support on HIV/STI prevention as well as PrEP initiation and/or adherence management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>WeChat mobile mini-application</intervention_name>
    <description>Sexual health education and the role of PrEP</description>
    <arm_group_label>WeChat mobile mini-application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 30&#xD;
&#xD;
          -  Engaged in at-risk sex. At risk sex is defined as sex with &gt;1 partner in the past 90&#xD;
             days, inconsistent condom use with vaginal or anal sex, ongoing sexual relationship&#xD;
             with an HIV-positive partner, participation in commercial sex work, or any bacterial&#xD;
             STI diagnosed or reported in the past 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History renal dysfunction&#xD;
&#xD;
          -  Chronic hepatitis B (HBV) infection&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Indication for HIV post-exposure prophylaxis&#xD;
&#xD;
          -  Signs and symptoms consistent with acute HIV infection&#xD;
&#xD;
          -  Outside the age range of 18-30&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aniruddha Hazra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anu Hazra, MD</last_name>
    <phone>773-795-2016</phone>
    <email>ahazra2@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renslow Sherer, MD</last_name>
    <phone>708-751-2340</phone>
    <email>rsherer@bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jinyintan Wuhan Infectious Disease Hospitals</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preexposure prophylaxis (PrEP), Prevention, mHealth</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

